A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment
about
Germline polymorphisms in SIPA1 are associated with metastasis and other indicators of poor prognosis in breast cancerBreast cancer in the personal genomics eraMolecular tumor profiling: translating genomic insights into clinical advancesAre BRCA1- and BRCA2-related breast cancers associated with increased mortality?Fine tuning chemotherapy to match BRCA1 statusPathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutationsBiomarkers in cancer staging, prognosis and treatment selectionHallmarks of 'BRCAness' in sporadic cancersPopulation-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2.Role of BRCA2 mutation status on overall survival among breast cancer patients from SardiniaBRCA1 interaction with human papillomavirus oncoproteins.Expression of estrogen receptor beta in the breast carcinoma of BRCA1 mutation carriersPotential excess mortality in BRCA1/2 mutation carriers beyond breast, ovarian, prostate, and pancreatic cancers, and melanoma.Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer.DNA methylome of familial breast cancer identifies distinct profiles defined by mutation status.The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study.BRCA1 missense polymorphisms are associated with poor prognosis of pancreatic cancer patients in a Chinese population.Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriersClassical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance.Genotype-phenotype correlations among BRCA1 4153delA and 5382insC mutation carriers from Latvia.The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancerHigh risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer.Properties of cellular and serum forms of thymidine kinase 1 (TK1) in dogs with acute lymphocytic leukemia (ALL) and canine mammary tumors (CMTs): implications for TK1 as a proliferation biomarker.Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers.The potential role of estrogen receptors and the SRC family as targets for the treatment of breast cancer.Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testingHereditary breast and ovarian cancer: new genes, new treatments, new concepts.Impact of Prophylactic Mastectomy in BRCA1/2 Mutation CarriersOutcome of triple-negative breast cancer in patients with or without deleterious BRCA mutationsWorse breast cancer prognosis of BRCA1/BRCA2 mutation carriers: what's the evidence? A systematic review with meta-analysis.The pathology of hereditary breast cancer.Breast cancer risks and risk prediction models.BRCA mutation testing in determining breast cancer therapy.Prophylactic and Therapeutic Breast Conservation in BRCA1/2 Mutation CarriersOnline tool to guide decisions for BRCA1/2 mutation carriers.Preoperative Systemic Treatment in BRCA-Positive Breast Cancer Patients: Case Report and Review of the Literature.Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women.Early onset breast cancer in Ashkenazi women carriers of founder BRCA1/2 mutations: beyond 10 years of follow-up.Tumor characteristics and prognosis in familial breast cancer.Risk-reducing Surgery in Women at Risk for Familial Breast or Ovarian Cancer.
P2860
Q21195235-7379AABE-449A-4B86-8486-45A0A5F52775Q24602679-296F5E07-A903-4C4E-B9C0-1CFAB0FF3024Q24797250-13A34AD9-EE6A-4626-A338-A0A78ADD6836Q24804064-774646BA-50B9-4A9A-8E6F-84CD5EB5334BQ27694529-58A20211-AEB1-4CC1-9CF4-885CA32A951FQ28265304-9784C8D4-7566-4AFF-9630-7595801683BDQ28278305-9AB93F19-1EAB-4397-8FDB-DAD26CC1B0F4Q29618825-531369FC-D4FC-4DDF-A37C-2DEA2040E8A1Q30432372-4D11FA97-5D82-4898-830D-B75A472C37DBQ30858718-F10B7E03-1964-4F7B-A2E0-831DDC07780BQ33292263-39175605-3EFD-4547-B4D5-B2DEC77C938AQ33327785-9D8E62D9-CC92-44D0-A900-4BBBA29007B4Q33416772-0B7C8DFF-7E74-408F-9AAE-F7A3929F1A15Q33539418-1EF2EAC1-42D0-469A-B8C7-68FF751ED852Q33708624-9875A18A-9F99-483E-9F1D-0E104277688FQ33739428-2CACE573-A22C-46A4-ABFC-433F2642FA52Q33829394-6886E3CF-C5F2-4F3E-915A-930B912ED06FQ33863531-0A69B3D3-513E-4DB6-AF97-F1AB0BEF57FCQ33903965-C3526021-F3DA-4782-B12C-67FC84D0ABF6Q34059765-8A32CCF9-E67E-4C1E-8139-8D2B7C80DA4CQ34102670-B4A70414-E2AF-4662-90B2-C7FB4DA84F35Q34240064-9E1EF2FD-D005-40BD-8A0A-EABE60AF3ADEQ34333126-6A7CBEB4-2088-412E-80B2-5F860AA0F6F6Q34663583-160B5ED4-10B0-4530-B5E0-471564DA87CCQ34982010-49711F96-A7D1-4141-B965-DE22EE241F06Q34994574-B007523F-87A1-4559-AAD0-878815513ED0Q35019634-5959CD03-37B4-426B-81B1-16C1F374CEE3Q35050959-59ED360B-6EF7-4E50-A9AF-D5CA39503BC6Q35100315-4DE691B6-4CEC-4191-B1C1-0D13226D331AQ35224593-13D6776E-7B81-49F6-BCFD-23198BCEDC0BQ35355084-C78F767B-BCFB-4CAB-8022-AC61384D9A45Q35399596-F6F237A3-5038-446F-9BC2-7DAE177ECCD7Q35619225-A7826F78-D4A5-4E9A-9291-D3EF2183171AQ35684391-375766CB-6B57-4CB0-B768-C91102AD7937Q35808372-86CE3007-6B8C-4A03-A59A-28911402D278Q35976084-1C9AE183-EE5F-496D-BB6C-48BB4142B5C7Q36119158-3F921F8A-49B8-45C0-AA71-6F63CC492F8DQ36160180-8E293C0B-F0F0-44DA-AB44-95EFA20782DEQ36207051-E3BB3ED1-874E-4840-8EB2-7EEA6F3A411CQ36295137-57342267-F083-4015-B8A0-B744956842B6
P2860
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment
description
2004 nî lūn-bûn
@nan
2004 թուականին հրատարակուած գիտական յօդուած
@hyw
2004 թվականին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
A combined analysis of outcome ...... stration of adjuvant treatment
@ast
A combined analysis of outcome ...... stration of adjuvant treatment
@en
A combined analysis of outcome ...... stration of adjuvant treatment
@nl
type
label
A combined analysis of outcome ...... stration of adjuvant treatment
@ast
A combined analysis of outcome ...... stration of adjuvant treatment
@en
A combined analysis of outcome ...... stration of adjuvant treatment
@nl
prefLabel
A combined analysis of outcome ...... stration of adjuvant treatment
@ast
A combined analysis of outcome ...... stration of adjuvant treatment
@en
A combined analysis of outcome ...... stration of adjuvant treatment
@nl
P2093
P2860
P50
P356
P1476
A combined analysis of outcome ...... stration of adjuvant treatment
@en
P2093
Clifford Hudis
David Roberge
John R Goffin
Louis R Bégin
Pierre O Chappuis
P2860
P2888
P304
P356
10.1186/BCR658
P407
P577
2004-01-01T00:00:00Z
P5875
P6179
1048068581